1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,110 | 1,150 | 16:46 | |
| 1,090 | 1,130 | 16:39 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01.12. | NanoViricides Has Signed a Master Services Agreement with OnlyOrphansCote Regarding Orphan Drug Strategy of NV-387 for Treatment of MPox, Smallpox, and Measles | 453 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / December 1, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development... ► Artikel lesen | |
| 26.11. | NANOVIRICIDES, INC. - 8-K, Current Report | - | SEC Filings | ||
| 17.11. | NanoViricides GAAP EPS of -$0.10 | 7 | Seeking Alpha | ||
| 17.11. | NanoViricides, Inc. Has Filed its Quarterly Report - Subsequent Raise Has Fortified Fiscal Position | 293 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / November 17, 2025 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal quarter... ► Artikel lesen | |
| 14.11. | NANOVIRICIDES, INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 14.11. | NanoViricides to Present at the Pharma Partnering Summit 2025 in Boston Today, November 14th - NV-387 is Effective Against H3N2 | 487 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / November 14, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs... ► Artikel lesen | |
| 12.11. | NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close | 548 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / November 12, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), today announced the closing of its previously announced securities purchase agreement... ► Artikel lesen | |
| NANOVIRICIDES Aktie jetzt für 0€ handeln | |||||
| 11.11. | NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close | 562 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / November 11, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), today announced that it has entered into a securities purchase agreement with a... ► Artikel lesen | |
| 10.11. | NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo | 563 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / November 10, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") today reported that it has received approval to Start Phase II Clinical Trial of... ► Artikel lesen | |
| 05.11. | NanoViricides Annual Shareholders Meeting to be Held at 10 am on Saturday, November 5th at on Saturday, November 8, 2025, at the Hampton Inn & Suites Stamford, CT | 530 | ACCESS Newswire | NV-387 Could be the Answer to the MPox Clade I Rising in the USA, Says Dr. Diwan SHELTON, CONNECTICUT / ACCESS Newswire / November 5, 2025 / NanoViricides, Inc. (NYSE American:NNVC ) (the "Company")... ► Artikel lesen | |
| 03.11. | NanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd | 452 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / November 3, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs... ► Artikel lesen | |
| 29.10. | Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive | 581 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / October 29, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), announced that Nanoviricides CEO Dr Anil Diwan joined Steve... ► Artikel lesen | |
| 27.10. | NanoViricides to Present at the PODD 2025 Conference in Boston on October 27 | 620 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / October 27, 2025 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the... ► Artikel lesen | |
| 22.10. | In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides | 520 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / October 22, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer:NNVC) (the "Company"), announced that its clinical lead drug NV-387 has shown strong... ► Artikel lesen | |
| 20.10. | A Measles Drug with Strong Activity without Toxicity Can Be Available Now for Emergency Use, Says NanoViricides - NV-387 Broad-Spectrum Antiviral with Activity Against Measles Virus | 541 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / October 20, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), announced that its clinical lead drug NV-387 has shown strong... ► Artikel lesen | |
| 15.10. | NanoViricides Dual Track Clinical Strategy Explained by a Research Report - Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage for MPox and also for Acute Respiratory Infections of All Viruses | 490 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / October 15, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that an analyst research report was published on the Company that explains... ► Artikel lesen | |
| 01.10. | NanoViricides verlängert Verträge mit Führungskräften und passt Kreditlinie an | 5 | Investing.com Deutsch | ||
| 01.10. | NANOVIRICIDES, INC. - 8-K, Current Report | 4 | SEC Filings | ||
| 30.09. | NanoViricides, Inc. Has Filed its Annual Report | 733 | ACCESS Newswire | Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage - NV-387 Could Become a Revolutionary Antiviral for Respiratory Viral Infections SHELTON, CONNECTICUT / ACCESS Newswire / September 30... ► Artikel lesen | |
| 29.09. | NANOVIRICIDES, INC. - 10-K, Annual Report | 9 | SEC Filings |
1 2 3 Weiter >>
47 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FORMYCON | 22,850 | -4,99 % | DAX-Check LIVE: Aurubis, Evotec, Formycon, Infineon, Porsche SE, Siemens Energy im Fokus | Die Erholung an der Börse hat sich zur Wochenmitte nicht fortgesetzt. Der DAX startete zwar mit kleinen Gewinnen in den Tag, rutschte im Verlauf jedoch ins Minus und schloss schließlich bei 23.694 Punkten... ► Artikel lesen | |
| NVE | 60,50 | +0,83 % | Dividendenbekanntmachungen (03.11.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADECOAGRO SA LU0584671464 0,1748 USD 0,1515 EUR AMERISERV FINANCIAL INC US03074A1025 0,03 USD 0,026 EUR AON PLC IE00BLP1HW54 0... ► Artikel lesen | |
| GAUZY | 1,310 | -4,38 % | Gauzy Ltd. - 6-K, Report of foreign issuer | ||
| VEECO INSTRUMENTS | 27,600 | -0,72 % | Veeco Instruments Inc.: Veeco Reports Third Quarter 2025 Financial Results | Third Quarter 2025 Highlights: Revenue of $165.9 million, compared with $184.8 million in the same period last yearGAAP net income of $10.6 million, or $0.17 per diluted share, compared with $22.0... ► Artikel lesen | |
| ONTO INNOVATION | 141,00 | +0,71 % | Onto Innovation Inc. (ONTO): A Bull Case Theory | ||
| NANOFORM FINLAND | 0,965 | +2,77 % | Nanoform Finland Oyj: Nanoform Q3 report: Momentum in kernels continues, commercial cGMP manufacturing license received, first near-term target for 2026 set | Nanoform Finland Plc | Company Release | November 12, 2025 at 08:10:00 EET
Our product kernels see good momentum. Nanoenzalutamide progresses with the fed arm of the pivotal human study. Licensing and... ► Artikel lesen | |
| KOPIN | 2,296 | -2,05 % | Kopin appoints new leadership to drive microdisplay technology roadmap | ||
| SOLESENCE | 2,120 | +7,61 % | Solésence, Inc.: Solésence Reports Third Quarter 2025 Financial Results | Advances Strategic Transformation with Key Changes in Executive Leadership, Product Development and Operations ROMEOVILLE, Ill., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN)... ► Artikel lesen | |
| DOTZ NANO | 0,027 | -5,26 % | DOTZ NANO LIMITED: Dotz to Present at Small Cap Growth Investor Conference | ||
| FENDX TECHNOLOGIES | 0,378 | +13,17 % | FendX Technologies Inc.: FendX Provides Corporate Update | Vancouver, British Columbia--(Newsfile Corp. - December 1, 2025) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D0) (the "Company" or "FendX"), an innovative surface protection company... ► Artikel lesen | |
| INSPLORION | 0,000 | 0,00 % | Insplorion AB: Quarterly report Q3 2025 | July - September
Outcome July - SeptemberNet sales amounted to 926 (490) kSEKProfit after financial items amounted to -3,133 (-3,459) kSEKEarnings per share before and after dilution: SEK -0,04 (-0... ► Artikel lesen | |
| ACACIA RESEARCH | 3,160 | -3,66 % | Acacia Research Non-GAAP EPS of -$0.01 beats by $0.13, revenue of $59.4M beats by $21.4M | ||
| ADVANCE ZINCTEK | 0,530 | 0,00 % | ADVANCE ZINCTEK LIMITED: Change of Director's Interest Notice - Lev Mizikovsky | ||
| LAMPETIA | 0,068 | +4,62 % | EQS-News: Lampetia AG: Halbjahresfinanzbericht auf neuer Webseite | EQS-News: Lampetia AG
/ Schlagwort(e): Halbjahresbericht
LAMPETIA AG: Halbjahresfinanzbericht auf neuer Webseite
30.09.2025 / 19:51 CET/CEST
Für den Inhalt der Mitteilung... ► Artikel lesen | |
| NANOFOCUS | 1,810 | 0,00 % | HV-Termine: Hauptversammlungen bei bioXXmed, Borussia Dortmund, CureVac, elexxion, Nanofocus, NSI Asset, OTRS | Einmal jährlich müssen sich Aufsichtsrat und Vorstand einer Gesellschaft den Aktionären stellen: Die Hauptversammlung ist das höchste Organ einer Aktiengesellschaft und vergleichbarer Unternehmens-Formen.... ► Artikel lesen |
NANOVIRICIDES INC gehört der Branche Nanotechnologie an. Die relative Kursveränderung beträgt aktuell -5,13 % bei einem Aktienkurs von 1,110 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NANOVIRICIDES INC finden Sie auf Wallstreet Online.